COMPARATIVE CLINICAL-TRIAL OF TETROXOPRIM-SULFADIAZINE AND AMPICILLIN IN THE TREATMENT OF PURULENT BRONCHIAL INFECTIONS

A clinical trial has been carried out comparing ten day courses of oral tetroxoprim, TXP, (100 mg) combined with sulphadiazine, SDZ, (250 mg), one tablet twice daily, with ampicillin, 500 mg four times daily in 60 patients with respiratory tract infections. TXP/SDZ was effective in treatment with an efficacy comparable with that of ampicillin. No side effects occurred in the TXP/SDZ group, whereas three patients taking ampicillin experienced gastrointestinal disturbances, in two cases necessitating withdrawal of treatment. Subsequent to the course of treatment there were more relapses in the TXP/SDZ group, although the difference from ampicillin was not significant. Abnormalities of liver function tests were found in similar numbers of patients in both treatment groups and appeared to be related to severity of illness rather than treatment. © 1979 Oxford University Press.